Navigation Links
Gen-Probe Announces Webcast of First Quarter 2011 Earnings Conference Call
Date:4/14/2011

SAN DIEGO, April 14, 2011 /PRNewswire/ -- Gen-Probe Incorporated (NASDAQ: GPRO) announced today that the Company will release its first quarter 2011 financial results on Thursday, April 28, 2011 at approximately 4:00 pm Eastern Time (ET). The announcement will be followed by a conference call with management at 4:30 pm ET.  

The conference call will be webcast live and may be accessed on the investors section of the Company's web site at www.gen-probe.com.  An archived version of the webcast will be available on the same web site for at least 90 days. A telephone replay also will be available for 24 hours after the call ends. To access the replay, please call 800-839-5573 (US) or 402-220-2075 (international).

About Gen-Probe

Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 28 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our most recent Form 10-K, and all subsequent periodic filings.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe Reports Financial Results for the Fourth Quarter and Full Year 2010
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2010 Earnings Conference Call
3. Gen-Probe to Webcast Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash
5. Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
6. Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments
7. Gen-Probe to Consolidate Industrial Assets Into New, Independent Company
8. Gen-Probe to Webcast Four Upcoming Investor Presentations
9. Gen-Probe to Webcast Two Upcoming Investor Presentations
10. Gen-Probe Completes Acquisition of Tepnel Life Sciences
11. Gen-Probe to Webcast Two Upcoming Investor Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... -- Market Research Future published a half-cooked research report on Global Cancer ... a CAGR of 12% during the period 2016 to 2022. ... ... division without any control. These abnormal cells have the ability to ... can spread to other parts of the body through the blood ...
(Date:1/17/2017)... ... January 17, 2017 , ... MS ... The new Balance™ GT Soybean Performance System will combine industry-leading genetics with a ... ingredient in the new Balance® Bean herbicide. The Balance™ GT Soybean Performance System ...
(Date:1/17/2017)... SAN DIEGO , Jan. 17, 2017 /PRNewswire/ ... Diego School of Medicine and St. Boniface Hospital ... treatments for peripheral neuropathy, an unmet health need ... in the Journal of Clinical Investigation, their results ... properties that prevent and reverse neuronal injury in ...
(Date:1/17/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... and earnings conference call will be broadcast live over ... a.m. Eastern Time.  A news release detailing the quarterly ... a.m. Eastern Time the morning of the conference call. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology Technology:
(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...
(Date:12/5/2016)... , Dec. 5, 2016  The Office of ... published "Can CT Scans Enhance or Replace Medico ... potential of supporting or replacing forensic autopsies with ... scan. In response to recommendations made ... exploring using CT scans as a potential component ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
Breaking Biology News(10 mins):